Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.
IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.